A clinical-stage cardiovascular company developing ninerafaxstat, a partial fatty acid oxidation (pFOX) inhibitor, with an initial focus in non-hypertrophic cardiomyopathy (nHCM) and pipeline-in-a-drug potential across other heart diseases.

Ninerafaxstat addresses the energy deficiency that underlies forms of heart disease by forcing the heart to use a more efficient ‘fuel’ source, aiming to balance energy supply with high demand. The drug mechanism has been validated in multiple forms of heart disease including nHCM, with clinical data showing a functional and symptomatic improvement in patients.